Corrections & Clarifications.(Correction notice)

An article in BioWorld Today, March 7, 2011, about BioSante Pharmaceuticals Inc. should have clarified that the company is conducting two LibiGel Phase III efficacy trials covered by an FDA-agreed special protocol assessment, and has completed enrollment of the first of the two. Its Phase III safety study for LibiGel has been ongoing since 2008, rather than being in the planning stage as stated in the article, and the study has enrolled more than 2,900 women to date.

Editor's note: The correction has been made in BioWorld Online.

Corrections & Clarifications.(Correction notice)

An article in BioWorld Today, March 7, 2011, about BioSante Pharmaceuticals Inc. should have clarified that the company is conducting two LibiGel Phase III efficacy trials covered by an FDA-agreed special protocol assessment, and has completed enrollment of the first of …